{"id":"atropine-sulfate-0-04-eye-drop","safety":{"commonSideEffects":[{"rate":null,"effect":"Mydriasis (pupil dilation)"},{"rate":null,"effect":"Cycloplegia (accommodation paralysis)"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Local irritation or hyperemia"},{"rate":null,"effect":"Systemic anticholinergic effects (rare with topical use)"}]},"_chembl":{"chemblId":"CHEMBL1396281","moleculeType":"Small molecule","molecularWeight":"387.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the iris sphincter muscle and ciliary muscle. This prevents acetylcholine-mediated contraction, resulting in mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). In the context of myopia control, atropine may work by relaxing accommodation-induced ciliary muscle tension and potentially altering scleral remodeling.","oneSentence":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:50.590Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mydriasis and cycloplegia for diagnostic purposes"},{"name":"Myopia control in children (off-label/emerging indication)"}]},"trialDetails":[{"nctId":"NCT07406399","phase":"PHASE4","title":"Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2023-06-30","conditions":"High Myopia, Low Concentration Atropine, Soft Contact Lens","enrollment":120},{"nctId":"NCT06523504","phase":"PHASE1, PHASE2","title":"Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control","status":"RECRUITING","sponsor":"Ruihua Wei","startDate":"2024-02-01","conditions":"Myopia","enrollment":410},{"nctId":"NCT07129889","phase":"NA","title":"Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Eye Hospital","startDate":"2025-12-02","conditions":"Myopia","enrollment":180},{"nctId":"NCT06708156","phase":"PHASE3","title":"The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression","status":"RECRUITING","sponsor":"Oupushifang Pharmaceutical Technology Co., Ltd.","startDate":"2024-06-15","conditions":"Myopia, Myopia Progression","enrollment":606},{"nctId":"NCT05939882","phase":"NA","title":"Low Concentration Atropine in the Prevention of Myopia in Children.","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2023-04-01","conditions":"Myopia, Progressive","enrollment":428},{"nctId":"NCT05357326","phase":"PHASE4","title":"Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model","status":"UNKNOWN","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2021-07-01","conditions":"Myopia","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atropine Sulfate 0.04% Eye Drop","genericName":"Atropine Sulfate 0.04% Eye Drop","companyName":"Shanghai Eye Disease Prevention and Treatment Center","companyId":"shanghai-eye-disease-prevention-and-treatment-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Mydriasis and cycloplegia for diagnostic purposes, Myopia control in children (off-label/emerging indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}